Related Experiment Video
Updated: Feb 17, 2026
Experimental and Imaging Techniques for Examining Fibrin Clot Structures in Normal and Diseased States
Published on: April 1, 2015
Postauthorization safety study of Clottafact® , a triply secured fibrinogen concentrate in acquired fibrinogen
C Négrier1, A-S Ducloy-Bouthors2, V Piriou3
1Edouard Herriot Hospital, Lyon, France.
Background And Objectives:
A postauthorization safety study was performed between 2009 and 2012 to describe the use of Clottafact® in acquired fibrinogen deficiency in real-life medical practice in France.
Materials And Methods:
One hundred and fifty patients were planned for 28 days of prospective follow-up after infusion. The analysis of this observational study was descriptive and performed according to the type of treatment (curative or preventive) and the origin of the bleed.
Results:
One hundred and fifty-six patients (16-87 years) were included in 13 centres and treated in five different medical bleeding situations: postpartum (59), other gynaecological/obstetrical (6), trauma (34), liver (13), cardiovascular (23) and other various bleeding situations (21). The mean follow-up time was 18·9 ± 12·3 days. Two patients presented adverse drug reactions: one a pulmonary embolism and the other a four-site venous thromboembolic episode. All were serious with a dubious causal relationship with the study treatment. Efficacy data were collected as a secondary objective. In 150 patients receiving curative treatment, 117 of 159 infusions (73·6%) were considered as successful by the investigators, 35 as moderate (22%) and seven as no response (4·4%).
Conclusion:
The Clottafact® safety profile observed during the study matched the known profile of fibrinogen during use.
Related Concept Videos
01:16Clot Retraction and Fibrinolysis
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins